Boehringer Ingelheim GmbH Ends Female Desire Drug Flibanserin Development After FDA’s Safety Query

October 8, 2010 |

1 min read

Twitter
LinkedIn
Facebook
Email
Print

Oct. 8 (Bloomberg) - Boehringer Ingelheim GmbH abandoned development of its female desire drug flibanserin after U.S. regulators said the pill wasn’t proven to be safe and effective.

Twitter
LinkedIn
Facebook
Email
Print

Regulatory Europe

Food and Drug Administration (FDA)